The role of the Wnt signaling pathway in incretin hormone production and function

Frontiers in Physiology

Volumn 3 JUL, Issue , 2012, Pages

  Chiang, Yu Ting A ^a,b   Ip, Wilfred ^a,b   Jin, Tianru ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Catenin; Gip; Glp 1; Insulin; Tcf7l2; Wnt signaling pathway

Indexed keywords

EID: 84866458660     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00273     Document Type: Review

References (125)

1. Ahlzen, M., Johansson, L. E., Cervin, C., Tornqvist, H., Groop, L., and Ridderstrale, M. (2008). Expression of the transcription factor 7-like 2 gene (TCF7L2) in human adipocytes is down regulated by insulin. Biochem. Biophys. Res. Commun. 370, 49-52.
2. Alibegovic, A. C., Sonne, M. P., Hojbjerre, L., Hansen, T., Pedersen, O., van Hall, G., Holst, J. J., Stallknecht, B., Dela, F., and Vaag, A. (2010). The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest. Diabetes 59, 836-843.
3. Baggio, L. L., and Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157.
4. Ban, K., Hui, S., Drucker, D. J., and Husain, M. (2009). Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hypertens. 3, 245-259.
5. Ban, K., Kim, K. H., Cho, C. K., Sauve, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., and Husain, M. (2010). Glucagon-like peptide (GLP)-1amide-mediated cytopro-tection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151, 1520-1531.
6. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., and Husain, M. (2008). Cardioprotective and vasodila-tory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117,2340-2350.
7. Bayliss, W. M., and Starling, E. H. (1902). The mechanism of pancreatic secretion. J. Physiol. 28, 325-353.
8. Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., and Najarian, R. C. (1983a). Exon duplication and divergence in the human preproglucagon gene. Nature 304, 368-371.
9. Bell, G. I., Santerre, R. F., and Mullenbach, G. T. (1983b). Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302, 716-718.
10. Brinkmeier, M. L., Potok, M. A., Davis, S. W., and Camper, S. A. (2007). TCF4 deficiency expands ventral diencephalon signaling and increases induction of pituitary progenitors. Dev. Biol. 311, 396-407.
11. Brown, J. C. (1971). A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can. J. Biochem. 49, 255-261.
12. Brown, J. C., and Dryburgh, J. R. (1971). A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can. J. Biochem. 49, 867-872.
13. Brown, J. C., Dryburgh, J. R., Ross, S. A., and Dupre, J. (1975). Identification and actions of gastric inhibitory polypeptide. Recent Prog. Horm.Res. 31,487-532.
14. Brubaker, P. L., and Drucker, D. J. (2004). Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145, 2653-2659.
15. Bullock, B. P., Heller, R. S., and Habener, J. E (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137,2968-2978.
16. Castrop, J., van Norren, K., and Clevers, H. (1992). A gene family of HMG-box transcription factors with homology to TCF-1. Nucleic Acids Res. 20,611.
17. Cauchi, S., Meyre, D., Choquet, H., Dina, C., Born, C., Marre, M., Balkau, B., and Froguel, P. (2006). TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 55,3189-3192.
18. Chang, Y. C., Chang, T. J., Jiang, Y. D., Kuo, S. S., Lee, K. C., Chiu, K. C., and Chuang, L. M. (2007). Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 56, 2631-2637.
19. Chen, J., Couto, E M., Minn, A. H., and Shalev, A. (2006). Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem. Biophys. Res. Commun. 346, 1067-1074.
20. Cho, Y. M., and Kieffer, T. J. (2010). K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam. Horm. 84, 111-150.
21. Cho, Y. M., and Kieffer, T. J. (2011). New aspects of an old drug: met-formin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 54, 219-222.
22. Columbus, J., Chiang, Y., Shao, W., Zhang, N., Wang, D., Gaisano, H. Y., Wang, Q., Irwin, D. M., and Jin, T. (2010). Insulin treatment and high-fat diet feeding reduces the expression of three Tcf genes in rodent pancreas. J. Endocrinol. 207, 77-86.
23. Cornelis, M. C., Qi, L., Kraft, P., and Hu, E B. (2009). TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am. J. Clin. Nutr. 89, 1256-1262.
24. Dabelea, D., Dolan, L. M., D'Agostino, R. Jr., Hernandez, A. M., McAteer, J. B., Hamman, R. F., Mayer-Davis, E. J., Marcovina, S., Lawrence, J. M., Pihoker, C., and Florez, J. C. (2011). Association testing of TCF7L2 polymorphisms with type 2 diabetes in multi-ethnic youth. Diabetologia 54, 535-539.
25. DasGupta, R., and Fuchs, E. (1999). Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 126, 4557-4568.
26. da Silva Xavier, G., Loder, M. K., McDonald, A., Tarasov, A. I., Carzaniga, R., Kronenberger, K., Barg, S., and Rutter, G. A. (2009). TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58, 894-905.
27. Ding, X., Saxena, N. K., Lin, S., Gupta, N. A., and Anania, E A. (2006). Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43, 173-181.
28. Drucker, D. J., Erlich, P., Asa, S. L., and Brubaker, P. L. (1996). Induction of intestinal epithelial proliferation by glucagon-like peptide Proc. Natl. Acad. Sci. U.S.A. 93, 7911-7916.
29. Duan, Q. L., Dube, M. P., Frasure-Smith, N., Barhdadi, A., Lesperance, E, Theroux, P., St-Onge, J., Rouleau, G. A., and McCaffery, J. M. (2007). Additive effects of obesity and TCF7L2 variants on risk for type 2 diabetes among cardiac patients. Diabetes Care 30, 1621-1623.
30. Duggirala, R., Blangero, J., Almasy, L., Dyer, T. D., Williams, K. L., Leach, R. J., O'Connell, P., and Stern, M. P. (1999). Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am.J. Hum. Genet. 64, 1127-1140.
31. Dupre, J., Ross, S. A., Watson, D., and Brown, J. C. (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37, 826-828.
32. Duval, A., Busson-Leconiat, M., Berger, R., and Hamelin, R. (2000). Assignment of the TCF-4 gene (TCF7L2) to human chromosome band 10q25.3. Cytogenet. Cell Genet. 88, 264-265.
33. D'Alessio, D. A., Fujimoto, W. Y., and Ensinck, J. W. (1989). Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38, 1534-1538.
34. Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., and Marks, V. (1993). Glucagon-like peptide-1 amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 138, 159-166.
35. Essers, M. A., de Vries-Smits, L. M., Barker, N., Polderman, P. E., Burgering, B. M., and Korswagen, H. C. (2005). Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308, 1181-1184.
36. Estall, J. L., and Drucker, D. J. (2006). Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 12, 1731-1750.
37. Florez, J. C. (2007). The new type 2 diabetes gene TCF7L2. Curr. Opin. Clin. Nutr. Metab. Care 10, 391-396.
38. Florez, J. C. (2008). Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51, 1100-1110.
39. Florez, J. C., Jablonski, K. A., Bayley, N., Pollin, T. I., de Bakker, P. I., Shuldiner, A. R., Knowler, W. C., Nathan, D. M., and Altshuler, D. (2006). TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl.J.Med. 355, 241-250.
40. Fujita, Y., Wideman, R. D., Asadi, A., Yang, G. K., Baker, R., Webber, T., Zhang, T., Wang, R., Ao, Z., Warnock, G. L., Kwok, Y. N., and Kieffer, T. J. (2010). Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138, 1966-1975.
41. Furstenau, U., Schwaninger, M., Blume, R., Jendrusch, E. M., and Knepel, W. (1999). Characterization of a novel calcium response element in the glucagon gene. J. Biol. Chem. 274, 5851-5860.
42. Garcia-Martinez, J. M., Chocarro-Calvo, A., Moya, C. M., and Garcia-Jimenez, C. (2009). WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 52, 1913-1924.
43. Gebhardt, R., and Hovhannisyan, A. (2010). Organ patterning in the adult stage: the role of Wnt/beta-catenin signaling in liver zona-tion and beyond. Dev. Dyn. 239, 45-55.
44. Gjesing, A. P., Kjems, L. L., Vestmar, M. A., Grarup, N., Linneberg, A., Deacon, C. F., Holst, J. J., Pedersen, O., and Hansen, T. (2011). Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test. Diabetologia 54, 103-110.
45. Gloyn, A. L., Braun, M., and Rorsman, P. (2009). Type 2 diabetes susceptibility gene TCF7L2 and its role in beta-cell function. Diabetes 58, 800-802.
46. Gonzalez-Sanchez, J. L., Martinez-Larrad, M. T., Zabena, C., Perez-Barba, M., and Serrano-Rios, M. (2008). Association of variants of the TCF7L2 gene with increases in the risk of type 2 diabetes and the proinsulin:insulin ratio in the Spanish population. Diabetologia 51, 1993-1997.
47. Grant, S. F., Hakonarson, H., and Schwartz, S. (2010). Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocr. Rev. 31, 183-193.
48. Grant, S. F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., Styrkarsdottir, U., Magnusson, K. P., Walters, G. B., Palsdottir, E., Jonsdottir, T., Gudmundsdottir, T., Gylfason, A., Saemundsdottir, J., Wilensky, R. L., Reilly, M. P., Rader, D. J., Bagger, Y., Christiansen, C., Gudnason, V., Sigurdsson, G., Thorsteinsdottir, U., Gulcher, J. R., Kong, A., and Stefansson, K. (2006). Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320-323.
49. Groop, L. (2010). Open chromatin and diabetes risk. Nat. Genet. 42, 190-192.
50. Groves, C. J., Zeggini, E., Minton, J., Frayling, T. M., Weedon, M. N., Rayner, N. W., Hitman, G. A., Walker, M., Wiltshire, S., Hattersley, A. T., and McCarthy, M. I. (2006). Association analysis of 6, 736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55, 2640-2644.
51. Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., and Anania, E A. (2010). Glucagon-like pep tide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584-1592.
52. Hansotia, T., and Drucker, D. J. (2005). GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul. Pept. 128, 125-134.
53. Hayes, M. R., Bradley, L., and Grill, H. J. (2009). Endogenous hindbrain glucagon-like pep tide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150, 2654-2659.
54. Hayes, M. R., Skibicka, K. P., and Grill, H. J. (2008). Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149,4059-4068.
55. Hino, S., Tanji, C., Nakayama, K. I., and Kikuchi, A. (2005). Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiq-uitination. Mol. Cell. Biol. 25, 9063-9072.
56. Jin, T. (2008). The WNT signalling pathway and diabetes mellitus. Diabetologia 51, 1771-1780.
57. Jin, T., George Fantus, I., and Sun, J. (2008). Wnt and beyond Wnt: multiple mechanisms control the tran-scriptional property of beta-catenin. Cell. Signal. 20, 1697-1704.
58. Jin, T., and Liu, L. (2008). The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol. Endocrinol. 22, 2383-2392.
59. Jin, T., Trinh, D. K., Wang, F., and Drucker, D. J. (1997). The caudal homeobox protein cdx-2/3 activates endogenous proglucagon gene expression in InR1-G9 islet cells. Mol. Endocrinol. 11,203-209.
60. Knauf, C., Cani, P. D., Ait-Belgnaoui, A., Benani, A., Dray, C., Cabou, C., Colom, A., Uldry, M., Rastrelli, S., Sabatier, E., Godet, N., Waget, A., Penicaud, L., Valet, P., and Burcelin, R. (2008). Brain glucagon-like pep-tide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149, 4768-4777.
61. Knauf, C., Cani, P. D., Perrin, C., Iglesias, M. A., Maury, J. F., Bernard, E., Benhamed, F., Gremeaux, T., Drucker, D. J., Kahn, C. R., Girard, J., Tanti, J. F., Delzenne, N. M., Postic, C., and Burcelin, R. (2005). Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 115,3554-3563.
62. Kolligs, E T., Hu, G., Dang, C. V., and Fearon, E. R. (1999). Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell. Biol. 19, 5696-5706.
63. Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kono, N., and Tarui, S. (1989). Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38, 902-905.
64. Krutzfeldt, J., and Stoffel, M. (2010). Regulation of wingless-type MMTV integration site family (WNT) signalling in pancreatic islets from wild-type and obese mice. Diabetologia 53, 123-127.
65. Kwan, E. P., Gao, X., Leung, Y. M., and Gaisano, H. Y. (2007). Activation of exchange protein directly activated by cyclic adenosine monophos-phate and protein kinase A regulate common and distinct steps in promoting plasma membrane exocytic and granule-to-granule fusions in rat islet beta cells. Pancreas 35, e45-e54.
66. Le Bacquer, O., Shu, L., Marchand, M., Neve, B., Paroni, F., Kerr Conte, J., Pattou, F., Froguel, P., and Maedler, K. (2011). TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum. Mol. Genet.20, 1906-1915.
67. Li, Y., Hansotia, T., Yusta, B., Ris, E, Halban, P. A., and Drucker, D. J. (2003). Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278, 471-478.
68. Light, P. E., Manning Fox, J. E., Riedel, M. J., and Wheeler, M. B. (2002). Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A-and ADP-dependent mechanism. Mol. Endocrinol. 16,2135-2144.
69. Liu, H., Fergusson, M. M., Wu, J. J., Rovira, I. I., Liu, J., Gavrilova, O., Lu, T., Bao, J., Han, D., Sack, M. N., and Finkel, T. (2011). Wnt signaling regulates hepatic metabolism. Sci. Signal. 4, ra6.
70. Liu, Z., and Habener, J. E (2008). Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 283, 8723-8735.
71. Liu, Z., Stanojevic, V., Brindamour, L. J., and Habener, J. E (2012). GLP1-derived nonapeptide GLP1 (28-36)amide protects pancreatic β-cells from glucolipotoxicity. J. Endocrinol. 213, 143-154.
72. Locke, J. M., Da Silva Xavier, G., Rutter, G. A., and Harries, L. W. (2011). An alternative polyadenylation signal in TCF7L2 generates isoforms that inhibit T cell factor/lymphoid-enhancer factor (TCF/LEF)-dependent target genes. Diabetologia 54, 3078-3082.
73. Lu, F., Jin, T., and Drucker, D. J. (1996). Proglucagon gene expression is induced by gastrin-releasing peptide in a mouse enteroen-docrine cell line. Endocrinology 137, 3710-3716.
74. Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., and Groop, L. (2008). Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359, 2220-2232.
75. Lyssenko, V., Lupi, R., Marchetti, P., Del Guerra, S., Orho-Melander, M., Almgren, P., Sjogren, M., Ling, C., Eriksson, K. F., Lethagen, A. L., Mancarella, R., Berglund, G., Tuomi, T., Nilsson, P., Del Prato, S., and Groop, L. (2007). Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 117, 2155-2163.
76. MacDonald, P. E., El-Kholy, W., Riedel, M. J., Salapatek, A. M., Light, P. E., and Wheeler, M. B. (2002). The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (SUPPL. 3), S434-S442.
77. MacDonald, P. E., Salapatek, A. M., and Wheeler, M. B. (2002). Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 51(SUPPL. 3), S443-S447.
78. Manolagas, S. C., and Almeida, M. (2007). Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 21, 2605-2614.
79. Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W E., and Nauck, M. A. (2003). Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 2719-2725.
80. Ng, M. C., Park, K. S., Oh, B., Tam, C. H., Cho, Y M., Shin, H. D., Lam, V K., Ma, R. C., So, W. Y., Cho, Y S., Kim, H. L., Lee, H. K., Chan, J. C., and Cho, N. H. (2008). Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6, 719 Asians. Diabetes 57,2226-2233.
81. Ni, Z., Anini, Y., Fang, X., Mills, G., Brubaker, P. L., and Jin, T. (2003). Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J. Biol. Chem. 278, 1380-1387.
82. Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y T., and Shannon, R. P. (2004). Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110,955-961.
83. Norton, L., Fourcaudot, M., Abdul-Ghani, M. A., Winnier, D., Mehta, E E, Jenkinson, C. P., and Defronzo, R. A. (2011). Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism. Diabetologia 54,3132-3142.
84. Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A. M., Zhou, Y. Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., and Drucker, D. J. (2009). GLP-1R agonist liraglutide activates cytoprotec-tive pathways and improves outcomes after experimental myocar-dial infarction in mice. Diabetes 58, 975-983.
85. Nyberg, J., Anderson, M. F., Meister, B., Alborn, A. M., Strom, A. K., Brederlau, A., Illerskog, A. C., Nilsson, O., Kieffer, T. J., Hietala, M. A., Ricksten, A., and Eriksson, P. S. (2005). Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 25, 1816-1825.
86. Osmark, P., Hansson, O., Jonsson, A., Ronn, T., Groop, L., and Renstrom, E. (2009). Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia 52, 850-854.
87. Pedersen, J., and Holst, J. J. (2011). Glucagon like-peptide 1 receptor and the liver. Liver Int. 31, 1243-1245.
88. Philippe, J. (1991). Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc. Natl. Acad. Sci. U.S.A. 88, 7224-7227.
89. Philippe, J., Mojsov, S., Drucker, D. J., and Habener, J. E (1986). Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology 119, 2833-2839.
90. Pilgaard, K., Jensen, C. B., Schou, J. H., Lyssenko, V., Wegner, L., Brons, C., Vilsboll, T., Hansen, T., Madsbad, S., Holst, J. J., Volund, A., Poulsen, P., Groop, L., Pedersen, O., and Vaag, A. A. (2009). The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52, 1298-1307.
91. Prokunina-Olsson, L., Kaplan, L. M., Schadt, E. E., and Collins, E S. (2009). Alternative splicing of TCF7L2 gene in omental and subcutaneous adipose tissue and risk of type 2 diabetes. PLoS ONE 4:e7231. doi: 10.1371/journal.pone.0007231
92. Prokunina-Olsson, L., Welch, C., Hansson, O., Adhikari, N., Scott, L. J., Usher, N., Tong, M., Sprau, A., Swift, A., Bonnycastle, L. L., Erdos, M. R., He, Z., Saxena, R., Harmon, B., Kotova, O., Hoffman, E. P., Altshuler, D., Groop, L., Boehnke, M., Collins, E S., and Hall, J. L. (2009). Tissue-specific alternative splicing of TCF7L2. Hum. Mol. Genet. 18, 3795-3804.
93. Prokunina-Olsson, L., and Hall, J. L. (2010). Evidence for neuroen-docrine function of a unique splicing form of TCF7L2 in human brain, islets and gut. Diabetologia 53,712-716.
94. Rask, E., Olsson, T., Soderberg, S., Johnson, O., Seckl, J., Holst, J. J., and Ahren, B. (2001). Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24, 1640-1645.
95. Reynisdottir, I., Thorleifsson, G., Benediktsson, R., Sigurdsson, G., Emilsson, V., Einarsdottir, A. S., Hjorleifsdottir, E. E., Orlygsdottir, G. T., Bjornsdottir, G. T., Saemundsdottir, J., Halldorsson, S., Hrafnkelsdottir, S., Sigurjonsdottir, S. B., Steinsdottir, S., Martin, M., Kochan, J. P., Rhees, B. K., Grant, S. F., Frigge, M. L., Kong, A., Gudnason, V., Stefansson, K., and Gulcher, J. R. (2003). Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2. Am. J. Hum. Genet. 73, 323-335.
96. Ross, S. A., Brown, J. C., and Dupre, J. (1977). Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26, 525-529.
97. Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., and MacDougald, O. A. (2000). Inhibition of adipoge-nesis by Wnt signaling. Science 289, 950-953.
98. Savic, D., Ye, H., Aneas, I., Park, S. Y., Bell, G. I., and Nobrega, M. A. (2011). Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. GenomeRes. 21, 1417-1425.
99. Schafer, S. A., Tschritter, O., Machicao, E, Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t'Hart, L. M., Nijpels, G., van Haeften, T. W., Haring, H. U., and Fritsche, A. (2007). Impaired glucagon-like peptide-1 -induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50, 2443-2450.
100. Schinner, S. (2009). Wnt-signalling and the metabolic syndrome. Horm. Metab. Res. 41, 159-163.
101. Schinner, S., Ulgen, F., Papewalis, C., Schott, M., Woelk, A., Vidal-Puig, A., and Scherbaum, W. A. (2008). Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 51, 147-154.
102. Scott, J., Selby, M., Urdea, M., Quiroga, M., Bell, G. I., and Rutter, W. J. (1983). Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor. Nature 302, 538-540.
103. Shao, W., Yu, Z., Fantus, I. G., and Jin, T. (2010). Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. Cell. Signal. 22, 1240-1246.
104. Shu, L., Matveyenko, A. V., Kerr-Conte, J., Cho, J. H., McIntosh, C. H., and Maedler, K. (2009). Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 18, 2388-2399.
105. Shu, L., Sauter, N. S., Schulthess, F. T., Matveyenko, A. V., Oberholzer, J., and Maedler, K. (2008). Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 57, 645-653.
106. Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., and Shannon, R. P. (2006). Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12, 694-699.
107. Sun, J., Khalid, S., Rozakis-Adcock, M., Fantus, I. G., and Jin, T. (2009). P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine. Oncogene 28, 3132-3144.
108. Sun, J., Wang, D., and Jin, T. (2010). Insulin alters the expression of components of the Wnt signaling pathway including TCF-4 in the intestinal cells. Biochim. Biophys. Acta 1800,344-351.
109. Taurin, S., Sandbo, N., Qin, Y., Browning, D., and Dulin, N. O. (2006). Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 281, 9971-9976.
110. Tomas, E., Stanojevic, V., and Habener, J. E (2011a). GLP-1-derived non-apeptide GLP-1 amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul. Pept. 167, 177-184.
111. Tomas, E., Wood, J. A., Stanojevic, V., and Habener, J. E (2011b). GLP-1-derived nonapeptide GLP-1amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul. Pept. 169, 43-48.
112. Tourrel, C., Bailbe, D., Meile, M. J., Kergoat, M., and Portha, B. (2001). Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50, 1562-1570.
113. Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., Wilding, J. P., Smith, D. M., Ghatei, M. A., Herbert, J., and Bloom, S. R. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
114. Unger, R. H., and Eisentraut, A. M. (1969). Entero-insular axis. Arch. Intern. Med. 123, 261-266.
115. Ussher, J. R., and Drucker, D. J. (2012). Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187-215.
116. Vacik, T., Stubbs, J. L., and Lemke, G. (2011). A novel mechanism for the transcriptional regulation of Wnt signaling in development. Genes Dev. 25, 1783-1795.
117. Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., and Holst, J. J. (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38, 665-673.
118. Wideman, R. D., and Kieffer, T. J. (2009). Mining incretin hormone pathways for novel therapies. Trends Endocrinol. Metab. 20, 280-286.
119. Xu, G., Stoffers, D. A., Habener, J. E, and Bonner-Weir, S. (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276.
120. Yi, F., Brubaker, P. L., and Jin, T. (2005). TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J. Biol. Chem. 280, 1457-1464.
121. Yi, F., Sun, J., Lim, G. E., Fantus, I. G., Brubaker, P. L., and Jin, T. (2008). Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 149, 2341-2351.
122. Yu, Z., and Jin, T. (2010). New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell. Signal. 22, 1-8.
123. Zhao, T., Parikh, P., Bhashyam, S., Bolukoglu, H., Poornima, I., Shen, Y. T., and Shannon, R. P. (2006). Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317,1106-1113.
124. Zhong, Q., Itokawa, T., Sridhar, S., Ding, K. H., Xie, D., Kang, B., Bollag, W. B., Bollag, R. J., Hamrick, M., Insogna, K., and Isales, C. M. (2007). Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am. J. Physiol. Endocrinol. Metab. 292, E543-E548.
125. Zhu, G., Wang, Y., Huang, B., Liang, J., Ding, Y., Xu, A., andWu, W. (2012). A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 31, 1001-1012.